Sign in →

Browse by Name

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #
 

Mayo Clinic Laboratories

Epic Code LAB1231688 Acetylcholine Receptor Modulating Antibody

Additional Codes

ARUP: 0099521

Interface: 1231688

Test Name Alias

ACHRMOD |  XARMO | Acetylcholine Modulating Ab

Ordering Instructions

Assessment of clinical activity of and initial diagnostic testing for myasthenia gravis. For reflexive panel, which contains binding, blocking, and modulating antibodies, refer to Acetylcholine Receptor Antibody Reflexive Panel

Collection Instructions

Specimen Collection: Blood

 

Container(s): Gold Top Serum Separator Tube (SST)

Preferred Volume to Collect: 5 mL

Minimum Volume to Collect: 1.0 mL

 

Collection Instructions:

  • Gold/Serum: Allow blood to clot for 30 minutes in a vertical position and centrifuge within 2 hours.

 

PROCESSING INSTRUCTIONS

Separate from cells ASAP or within 2 hours of collection.

Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)

Specimen Transport Temperature

REFRIGERATED

Rejection Criteria

  • Contaminated
  • Hemolyzed
  • Severely lipemic

Specimen Stability

After separation from cells

Ambient: 48 hours

Refrigerate: 2 weeks

Frozen: 1 year (avoid repeated freeze/thaw cycles)

Test Frequency

Available Sun-Fri reported in 2-7 days after receipt at ARUP Lab

Reference Range

Components: Acetylcholine Modulating Antibody 

Reference Interval: 45 or less modulating

Interpretive Data

Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Component Interpretation
Acetylcholine Receptor Modulating Antibody Negative:  0-45% modulating
Positive:  46% or greater modulating

Performing Department

Send out to ARUP Ref. Lab

Performing Department Laboratory Location

REFERRAL SEND OUTS

Methodology

Semi-Quantitative Flow Cytometry

CPT

86043

CDM Code

3028604302

Epic Test ID

123010353

LOINC

30192-9

Reviewed Date

4/2/2025 - Added to catalog